Table 4:
Univariable and multivariable models of the impact of disease activity states on specific organ damage accrual.
| Univariable | Multivariable* | |
|---|---|---|
| Odds Ratio, OR (95% CI) | OR (95% CI) | |
| Ophthalmologic | ||
| Remission off treatment | 0.88 (0.77–1.01) | 0.84 (0.72–0.97) |
| Remission on treatment | 0.79 (0.64–0.96) | 0.72 (0.59–0.88) |
| LDA-TC | 0.71 (0.52–0.96) | 0.69 (0.50–0.94) |
| mLLDAS | 0.91 (0.71–1.17) | 0.88 (0.69–1.13) |
| Neuropsychiatric | ||
| Remission off treatment | 0.80 (0.68–0.99) | 0.85 (0.73–0.99) |
| Remission on treatment | 0.55 (0.42–0.72) | 0.66 (0.53–0.82) |
| LDA-TC | 0.75 (0.51–1.09) | 0.76 (0.54–1.05) |
| mLLDAS | 0.63 (0.40–1.00) | 0.75 (0.53–1.05) |
| Renal | ||
| Remission off treatment | 0.52 (0.39–0.67) | 0.71 (0.54–0.92) |
| Remission on treatment | 0.43 (0.31–0.61) | 0.54 (0.38–0.78) |
| LDA-TC | 0.12 (0.03–0.51) | 0.27 (0.10–0.77) |
| mLLDAS | 0.43 (0.22–0.87) | 0.65 (0.36–1.17) |
| Lung | ||
| Remission off treatment | 0.59 (0.44–0.80) | 0.71 (0.53–0.95) |
| Remission on treatment | 0.77 (0.59–0.99) | 0.85 (0.68–1.07) |
| LDA-TC | 0.52 (0.29–0.92) | 0.63 (0.40–1.01) |
| mLLDAS | 0.58 (0.34–1.00) | 0.68 (0.43–1.07) |
| Cardiovascular | ||
| Remission off treatment | 0.79 (0.64–0.99) | 0.73 (0.58–0.92) |
| Remission on treatment | 0.70 (0.53–0.93) | 0.66 (0.51–0.92) |
| LDA-TC | 0.97 (0.73–1.30) | 0.89 (0.68–1.17) |
| mLLDAS | 0.64 (0.36–1.10) | 0.62 (0.36–1.05) |
| Peripheral vascular | ||
| Remission off treatment | 0.89 (0.69–1.15) | 0.97 (0.75–1.25) |
| Remission on treatment | 0.66 (0.45–0.98) | 0.75 (0.52–1.08) |
| LDA-TC | 0.03 (0.00–0.83) | 0.06 (0.00–0.87) |
| mLLDAS | 1.07 (0.68–1.67) | 1.16 (0.78–1.72) |
| Gastrointestinal | ||
| Remission off treatment | 1.02 (0.79–1.33) | 1.05 (0.81–1.37) |
| Remission on treatment | 1.12 (0.81–1.56) | 1.17 (0.86–1.59) |
| LDA-TC | 0.99 (0.58–1.70) | 1.01 (0.60–1.69) |
| mLLDAS | 1.14 (0.66–1.96) | 1.27 (0.77–2.09) |
| Musculoskeletal | ||
| Remission off treatment | 0.89 (0.83–0.96) | 0.70 (0.58–0.84) |
| Remission on treatment | 0.93 (0.84–1.02) | 0.77 (0.62–0.94) |
| LDA-TC | 0.96 (0.85–1.08) | 0.82 (0.62–1.09) |
| mLLDAS | 1.04 (0.92–1.17) | 0.92 (0.69–1.22) |
| Skin | ||
| Remission off treatment | 0.66 (0.52–0.85) | 0.69 (0.53–0.90) |
| Remission on treatment | 0.47 (0.32–0.70) | 0.52 (0.36–0.75) |
| LDA-TC | 1.07 (0.85–1.36) | 1.06 (0.82–1.37) |
| mLLDAS | 0.71 (0.44–1.13) | 0.72 (0.46–1.12) |
| Gonadal | ||
| Remission off treatment | 0.43 (0.22–0.84) | 0.48 (0.25–0.94) |
| Remission on treatment | 0.68 (0.39–1.19) | 0.77 (0.45–1.32) |
| LDA-TC | 1.07 (0.63–1.83) | 1.12 (0.66–1.89) |
| mLLDAS | 0.48 (0.11–2.09) | 0.65 (0.18–2.30) |
| Diabetes | ||
| Remission off treatment | 0.73 (0.50–1.05) | 0.73 (0.51–1.05) |
| Remission on treatment | 0.60 (0.35–1.02) | 0.61 (0.37–1.02) |
| LDA-TC | 0.67 (0.24–1.83) | 0.66 (0.25–1.74) |
| mLLDAS | 0.28 (0.11–0.69) | 0.32 (0.16–0.64) |
| Cancer | ||
| Remission off treatment | 1.24 (1.00–1.53) | 1.10 (0.87–1.40) |
| Remission on treatment | 1.36 (1.05–1.76) | 1.19 (0.90–1.56) |
| LDA-TC | 1.10 (0.71–1.70) | 1.03 (0.65–1.63) |
| mLLDAS | 1.28 (0.86–1.89) | 1.17 (0.79–1.73) |
*
Adjusted for included sex, age at diagnosis, race/ethnicity, education, baseline disease duration, follow-up time the highest-ever glucocorticoid dose prior to cohort entry, antimalarials and the score of the same organ damage. LDA-TC: Low disease activity Toronto Cohort definition. mLLDAS: modified Lupus low disease activity state.